Eli Lilly and Company (NYSE: LLY) will present new clinical and real-world research in people with knee osteoarthritis pain ...

T2D-2, the first Phase 3 trial comparing retatrutide with another incretin medicine, retatrutide delivered greater A1C reduction and more than double the weight loss of the highest approved dose of ...

Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced positive results from ATTAIN-OSA, a Phase 3 clinical program evaluating the efficacy and safety of Foundayo ...

After years of thinking she should be able to manage her weight on her own, Leanne shares how a conversation with her doctor ...

After comparing both platforms, I found Kalshi easier to navigate, particularly for U.S. users new to prediction markets. Its straightforward sign-up process and intuitive mobile app give it a ...

EOG Resources, Inc. (EOG) today reported third quarter 2026 results. The attached schedules for the reconciliation of non-GAAP measures to GA ...

For more than a decade, inter partes review (IPR) was the tool of choice for trying to invalidate a patent. That is changing.

Q3 2026 Adjusted EBITDA was a loss of $178.5 million, which is on the favorable end of the guidance range of $170 million - ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Florida’s governor’s race is producing sharply conflicting polling ...

Apple and Samsung, hardened rivals, both have passport-sized folding phones that are packed with features, come with compromises, and cost a lot. If you can't decide which option is better, we're here ...